Computational models for predicting interactions with membrane transporters

Current Medicinal Chemistry

Volumn 20, Issue 16, 2013, Pages 2118-2136

  Xu, Y ^a   Shen, Q ^a   Liu, X ^a   Lu, J ^a   Li, S ^a   Luo, C ^a   Gong, L ^a   Luo, X ^a   Zheng, M ^a   Jiang, H ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Computational methods; Homology modeling; Membrane transporter; Phamacophore models; QSAR models; Supervised unsupervised learning algorithms

Indexed keywords

ABC TRANSPORTER; AMPHOPHILE; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; MEMBRANE TRANSPORTER; MULTIDRUG AND TOXIN EXTRUSION TRANSPORTER 1; MULTIDRUG AND TOXIN EXTRUSION TRANSPORTER 2; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 10; MULTIDRUG RESISTANCE PROTEIN 11; MULTIDRUG RESISTANCE PROTEIN 12; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 2; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL NEURAL NETWORK; COMPUTER MODEL; EXON; HUMAN; HYDROGEN BOND; HYDROLYSIS; HYDROPHOBICITY; MOLECULAR DOCKING; NONHUMAN; OXIDATIVE STRESS; PHARMACOPHORE; PHENOTYPE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; COMPUTER SIMULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84877954939     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320160005     Document Type: Article

References (139)

1. Schinkel, A.H.; Mayer, U.; Wagenaar, E.; Mol, C.A.A.M.; Van Deemter, L.; Smit, J.J.M.; Van Der Valk, M.A.; Voordouw, A.C.; Spits, H.; Van Tellingen, O., Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) Pglycoproteins. Proc. Natl. Acad. Sci., 1997, 94 (8), 4028-4033. (Pubitemid 27180493)
2. Wijnholds, J.; De Lange, E.; Scheffer, G.L.; Mol, C.; van der Valk, M.; Schinkel, A.; Scheper, R.; Breimer, D.; Borst, P., Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest., 2000, 105 (3), 279-285. (Pubitemid 30094447)
3. Denk, G.U.; Soroka, C.J.; Takeyama, Y.; Chen, W.S.; Schuetz, J.D.; Boyer, J.L., Multidrug resistance-associated protein 4 is upregulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J. Hepatol., 2004, 40 (4), 585-591. (Pubitemid 38367779)
4. Jonker, J.W.; Wagenaar, E.; Van Eijl, S.; Schinkel, A.H., Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol. Cell Biol., 2003, 23 (21), 7902-7908. (Pubitemid 37271485)
5. Sweet, D.H.; Miller, D.S.; Pritchard, J.B.; Fujiwara, Y.; Beier, D.R.; Nigam, S.K., Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J. Biol. Chem., 2002, 277 (30), 26934-26943. (Pubitemid 34951703)
6. Rubio-Aliaga, I.; Frey, I.; Boll, M.; Groneberg, D.A.; Eichinger, H.M.; Balling, R.; Daniel, H., Targeted disruption of the peptide transporter Pept2 gene in mice defines its physiological role in the kidney. Mol. Cell Biol., 2003, 23 (9), 3247-3252. (Pubitemid 36459237)
7. Wang, D.S.; Jonker, J.W.; Kato, Y.; Kusuhara, H.; Schinkel, A.H.; Sugiyama, Y., Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther., 2002, 302 (2), 510-515. (Pubitemid 34787213)
8. Nies, A.T.; Keppler, D., The apical conjugate efflux pump ABCC2 (MRP2). Pfllügers. Arch., 2007, 453 (5), 643-659. (Pubitemid 46192536)
9. Lahjouji, K.; Mitchell, G.A.; Qureshi, I.A., Carnitine transport by organic cation transporters and systemic carnitine deficiency. Mol. Genet. Metab., 2001, 73 (4), 287-297. (Pubitemid 32846367)
10. Prentis, R.; Lis, Y.; Walker, S., Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Brit. J. Clin. Pharmaco, 1988, 25 (3), 387-396.
11. Giacomini, K.M.; Huang, S.M.; Tweedie, D.J.; Benet, L.Z.; Brouwer, K.L.R.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K.M., Membrane transporters in drug development. Nat. Rev. Drug Discovery, 2010, 9 (3), 215-236.
12. Estrada, E.; Molina, E.; Nodarse, D.; Uriarte, E., Structural Contributions of Substrates to their Binding to P-Glycoprotein. A TOPSMODE Approach. Curr. Pharm. Des., 2010, 16 (24), 2676-2709.
13. Cascorbi, I., Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Therapeut., 2006, 112 (2), 457-473. (Pubitemid 44486412)
14. Syvänen, S.; Lindhe, Ö.; Palner, M.; Kornum, B.R.; Rahman, O.; Langström, B.; Knudsen, G.M.; Hammarlund-Udenaes, M., Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycopro tein transport. Drug Metab. Dispos., 2009, 37 (3), 635-643.
15. Buist, S.C.N.; Klaassen, C.D., Rat and mouse differences in gender-predominant expression of organic anion transporter (Oat1-3; Slc22a6-8) mRNA levels. Drug Metab. Dispos., 2004, 32 (6), 620-625. (Pubitemid 38668154)
16. Urakami, Y.; Nakamura, N.; Takahashi, K.; Okuda, M.; Saito, H.; Hashimoto, Y.; Inui, K., Gender differences in expression of organic cation transporter OCT2 in rat kidney. Febs. Lett., 1999, 461 (3), 339-342. (Pubitemid 29533359)
17. Cherrington, N.J.; Slitt, A.L.; Maher, J.M.; Zhang, X.X.; Zhang, J.; Huang, W.; Wan, Y.J.Y.; Moore, D.D.; Klaassen, C.D., Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor. Drug Metab. Dispos., 2003, 31 (11), 1315-1319. (Pubitemid 37310319)
18. Chen, C.; Klaassen, C.D., Rat multidrug resistance protein 4 (Mrp4, Abcc4): Molecular cloning, organ distribution, postnatal renal expression, and chemical inducibility. Biochem. Bioph. Res. Co, 2004, 317 (1), 46-53. (Pubitemid 38401963)
19. Kerb, R.; Brinkmann, U.; Chatskaia, N.; Gorbunov, D.; Gorboulev, V.; Mornhinweg, E.; Keil, A.; Eichelbaum, M.; Koepsell, H., Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics and Genomics, 2002, 12 (8), 591-595. (Pubitemid 36005667)
20. Kajinami, K.; Brousseau, M.E.; Ordovas, J.M.; Schaefer, E.J., Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. The American journal of cardiology, 2004, 93 (8), 1046-1050. (Pubitemid 38479466)
21. Balram, C.; Sharma, A.; Sivathasan, C.; Lee, E.J.D., Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: Phenotypic-genotypic correlates. Brit. J. Clin. Pharmaco, 2003, 56 (1), 78-83. (Pubitemid 36886491)
22. Ueda, K.; Clark, D.; Chen, C.; Roninson, I.; Gottesman, M.; Pastan, I., The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J. Biol. Chem., 1987, 262 (2), 505-508. (Pubitemid 17005205)
23. Kim, R.B.; Fromm, M.F.; Wandel, C.; Leake, B.; Wood, A.; Roden, D.M.; Wilkinson, G.R., The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 1998, 101 (2), 289-294. (Pubitemid 28067324)
24. Cole, S.; Bhardwaj, G.; Gerlach, J.; Mackie, J.; Grant, C.; Almquist, K.; Stewart, A.; Kurz, E.; Duncan, A.; Deeley, R., Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 1992, 258 (5088), 1650-1654. (Pubitemid 23012438)
25. Jedlitschky, G.; Leier, I.; Buchholz, U.; Center, M.; Keppler, D., ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res., 1994, 54 (18), 4833-4836. (Pubitemid 24289409)
26. Bortfeld, M.; Rius, M.; König, J.; Herold-Mende, C.; Nies, A.; Keppler, D., Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience, 2006, 137 (4), 1247-1257. (Pubitemid 43133150)
27. Keppler, D., Multidrug resistance proteins (MRPs, ABCCs): Importance for pathophysiology and drug therapy. Drug Transporters, 2011, 201, 299-323.
28. Leier, I.; Jedlitschky, G.; Buchholz, U.; Cole, S.; Deeley, R.G.; Keppler, D., The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem., 1994, 269 (45), 27807-27810. (Pubitemid 24354499)
29. Cole, S.P.C.; Deeley, R.G., Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol. Sci, 2006, 27 (8), 438-446. (Pubitemid 44051570)
30. Borst, P.; De Wolf, C.; Van De Wetering, K., Multidrug resistanceassociated proteins 3, 4, and 5. Pfllügers. Arch., 2007, 453 (5), 661-673.
31. Cole, S.P.C.; Sparks, K.E.; Fraser, K.; Loe, D.W.; Grant, C.E.; Wilson, G.M.; Deeley, R.G., Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 1994, 54 (22), 5902-5910. (Pubitemid 24375226)
32. Cui, Y.; König, J.; Buchholz, U.; Spring, H.; Leier, I.; Keppler, D., Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol., 1999, 55 (5), 929-937. (Pubitemid 29214613)
33. Zeng, H.; Bain, L.J.; Belinsky, M.G.; Kruh, G.D., Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res., 1999, 59 (23), 5964-5967. (Pubitemid 30004958)
34. Schuetz, J.D.; Connelly, M.C.; Sun, D.; Paibir, S.G.; Flynn, P.M.; Srinivas, R.; Kumar, A.; Fridland, A., MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med., 1999, 5 (9), 1048-1051. (Pubitemid 29439577)
35. McAleer, M.A.; Breen, M.A.; White, N.L.; Matthews, N., pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J. Biol. Chem., 1999, 274 (33), 23541-23548.
36. Pratt, S.; Shepard, R.L.; Kandasamy, R.A.; Johnston, P.A.; Perry, W.; Dantzig, A.H., The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol. Cancer Ther., 2005, 4 (5), 855-863. (Pubitemid 40767130)
37. Belinsky, M.G.; Chen, Z.S.; Shchaveleva, I.; Zeng, H.; Kruh, G.D., Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res., 2002, 62 (21), 6172-6177. (Pubitemid 35244468)
38. Hopper-Borge, E.; Chen, Z.S.; Shchaveleva, I.; Belinsky, M.G.; Kruh, G.D., Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10). Cancer Res., 2004, 64 (14), 4927-4930. (Pubitemid 38924539)
39. Guo, Y.; Kotova, E.; Chen, Z.S.; Lee, K.; Hopper-Borge, E.; Belinsky, M.G.; Kruh, G.D., MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2', 3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl) adenine. J. Biol. Chem., 2003, 278 (32), 29509-29514. (Pubitemid 36962331)
40. Fetsch, P.A.; Abati, A.; Litman, T.; Morisaki, K.; Honjo, Y.; Mittal, K.; Bates, S.E., Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett., 2006, 235 (1), 84-92.
41. van Herwaarden, A.E.; Schinkel, A.H., The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol. Sci., 2006, 27 (1), 10-16. (Pubitemid 43063119)
42. Kellner, U.; Hutchinson, L.; Seidel, A.; Lage, H.; Danks, M.K.; Dietel, M.; Kaufmann, S.H., Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of Pglycoprotein. Int. J. Cancer, 1997, 71 (5), 817-824. (Pubitemid 27237204)
43. Burger, H.; Van Tol, H.; Boersma, A.W.M.; Brok, M.; Wiemer, E.A.C.; Stoter, G.; Nooter, K., Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood, 2004, 104 (9), 2940-2942. (Pubitemid 39434984)
44. Nagashima, S.; Soda, H.; Oka, M.; Kitazaki, T.; Shiozawa, K.; Nakamura, Y.; Takemura, M.; Yabuuchi, H.; Fukuda, M.; Tsukamoto, K., BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer Chemoth. Pharm., 2006, 58 (5), 594-600. (Pubitemid 44167384)
45. Saito, H.; Hirano, H.; Nakagawa, H.; Fukami, T.; Oosumi, K.; Murakami, K.; Kimura, H.; Kouchi, T.; Konomi, M.; Tao, E., A new strategy of high-speed screening and quantitative structureactivity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J. Pharmacol. Exp. Ther., 2006, 317 (3), 1114-1124. (Pubitemid 43764115)
46. Ross, D.D.; Karp, J.E.; Chen, T.T.; Doyle, L.A., Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood, 2000, 96 (1), 365-368. (Pubitemid 30456496)
47. van der Kolk, D.M.; Vellenga, E.; Scheffer, G.L.; Müller, M.; Bates, S.E.; Scheper, R.J.; de Vries, E.G.E., Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood, 2002, 99 (10), 3763-3770. (Pubitemid 34534549)
48. Gründemann, D.; Gorboulev, V.; Gambaryan, S.; Veyhl, M.; Koepsell, H., Drug excretion mediated by a new prototype of polyspecific transporter. Nature, 1994, 372 (6506), 549-552. (Pubitemid 24368536)
49. Jonker, J.W.; Schinkel, A.H., Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther., 2004, 308 (1), 2-9. (Pubitemid 38090693)
50. Kimura, N.; Masuda, S.; Tanihara, Y.; Ueo, H.; Okuda, M.; Katsura, T.; Inui, K.I., Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet., 2005, 20 (5), 379-386.
51. Wu, X.; Kekuda, R.; Huang, W.; Fei, Y.J.; Leibach, F.H.; Chen, J.; Conway, S.J.; Ganapathy, V., Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J. Biol. Chem., 1998, 273 (49), 32776-32786. (Pubitemid 28557664)
52. Kimura, H.; Takeda, M.; Narikawa, S.; Enomoto, A.; Ichida, K.; Endou, H., Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J. Pharmacol. Exp. Ther., 2002, 301 (1), 293-298. (Pubitemid 34250307)
53. Sweet, D.H.; Bush, K.T.; Nigam, S.K., The organic anion transporter family: From physiology to ontogeny and the clinic. Am. J. Physiol-renal., 2001, 281 (2), F197-F205.
54. Buist, S.C.N.; Cherrington, N.J.; Choudhuri, S.; Hartley, D.P.; Klaassen, C.D., Gender-specific and developmental influences on the expression of rat organic anion transporters. J. Pharmacol. Exp. Ther, 2002, 301 (1), 145-151. (Pubitemid 34250290)
55. Nakajima, N.; Sekine, T.; Cha, S.H.; Tojo, A.; Hosoyamada, M.; Kanai, Y.; Yan, K.; Awa, S.; Endou, H., Developmental changes in multispecific organic anion transporter 1 expression in the rat kidney1. Kidney Int., 2000, 57 (4), 1608-1616. (Pubitemid 30207919)
56. Cihlar, T.; Lin, D.C.; Pritchard, J.B.; Fuller, M.D.; Mendel, D.B.; Sweet, D.H., The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol., 1999, 56 (3), 570-580. (Pubitemid 29406884)
57. Race, J.A.E.; Grassl, S.M.; Williams, W.J.; Holtzman, E.J., Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem. Bioph. Res. Co., 1999, 255 (2), 508-514. (Pubitemid 29292290)
58. Sekine, T.; Cha, S.H.; Tsuda, M.; Apiwattanakul, N.; Nakajima, N.; Kanai, Y.; Endou, H., Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. Febs. Lett., 1998, 429 (2), 179-182. (Pubitemid 28288205)
59. Cha, S.H.; Sekine, T.; Kusuhara, H.; Yu, E.; Kim, J.Y.; Sugiyama, Y.; Kanai, Y.; Endou, H., Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J. Biol. Chem., 2000, 275 (6), 4507-4512. (Pubitemid 30094696)
60. Eraly, S.A.; Bush, K.T.; Sampogna, R.V.; Bhatnagar, V.; Nigam, S.K., The molecular pharmacology of organic anion transporters: From DNA to FDA? Mol. Pharmacol., 2004, 65 (3), 479-487. (Pubitemid 38264013)
61. Sekine, T.; Cha, S.H.; Endou, H., The multispecific organic anion transporter (OAT) family. Pfllügers. Arch., 2000, 440 (3), 337-350. (Pubitemid 30445708)
62. Hagenbuch, B.; Meier, P.J., Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pfllügers. Arch., 2004, 447 (5), 653-665. (Pubitemid 38241451)
63. Hagenbuch, B.; Meier, P., The superfamily of organic anion transporting polypeptides. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2003, 1609 (1), 1-18. (Pubitemid 36044060)
64. Kim, R., Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur. J. Clin. Invest., 2003, 33 (Suppl.2), 1-5.
65. Morita, Y.; Kodama, K.; Shiota, S.; Mine, T.; Kataoka, A.; Mizushima, T.; Tsuchiya, T., NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob. Agents. Ch., 1998, 42 (7), 1778-1782. (Pubitemid 28311578)
66. Brown, M.H.; Paulsen, I.T.; Skurray, R.A., The multidrug efflux protein NorM is a prototype of a new family of transporters. Mol. Microbiol., 1999, 31 (1), 394-395. (Pubitemid 29012178)
67. Otsuka, M.; Matsumoto, T.; Morimoto, R.; Arioka, S.; Omote, H.; Moriyama, Y., A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. U S A, 2005, 102 (50), 17923-17928. (Pubitemid 41798478)
68. Masuda, S.; Terada, T.; Yonezawa, A.; Tanihara, Y.; Kishimoto, K.; Katsura, T.; Ogawa, O.; Inui, K., Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol., 2006, 17 (8), 2127-2135. (Pubitemid 44141902)
69. Yonezawa, A.; Inui, K., Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Brit. J. Pharmacol., 2011, 164 (7), 1817-1825.
70. Tanihara, Y.; Masuda, S.; Sato, T.; Katsura, T.; Ogawa, O.; Inui, K., Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters. Biochem. Pharmacol., 2007, 74 (2), 359-371. (Pubitemid 46890818)
71. Tsuda, M.; Terada, T.; Asaka, J.-i.; Ueba, M.; Katsura, T.; Inui, K.-i., Oppositely directed H(+) gradient functions as a driving force of rat H(+)/organic cation antiporter MATE1. Am. J. Physiol-renal., 2007, 292 (2), F593-F598. (Pubitemid 46220526)
72. Winter, T.N.; Elmquist, W.F.; Fairbanks, C.A., OCT2 and MATE1 provide bidirectional agmatine transport. Mol. Pharmaceut., 2011, 8 (1), 133-142.
73. Koenig, J.; Zolk, O.; Singer, K.; Hoffmann, C.; Fromm, M.F., Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: Determinants of uptake and transcellular translocation of organic cations. Brit. J. Pharmacol., 2011, 163 (3), 546-555.
74. Wang, L.L.; Liu, Y.H.; Meng, L.L.; Li, C.G.; Zhou, S.F., Phenotype Prediction of Non-Synonymous Single-Nucleotide Polymorphisms in Human ATP-Binding Cassette Transporter Genes. Basic Clin. Pharmacol. Toxicol., 2011, 108 (2), 94-114.
75. Rajagopalan, L.; Patel, N.; Madabushi, S.; Goddard, J.A.; Anjan, V.; Lin, F.; Shope, C.; Farrell, B.; Lichtarge, O.; Davidson, A.L., Essential helix interactions in the anion transporter domain of prestin revealed by evolutionary trace analysis. J. Neurosci., 2006, 26 (49), 12727-12734. (Pubitemid 44904568)
76. Chang, C.; Swaan, P.W., Computational approaches to modeling drug transporters. Eur. J. Pharm. Sci., 2006, 27 (5), 411-424. (Pubitemid 43363337)
77. Rosenberg, M.F.; Kamis, A.B.; Callaghan, R.; Higgins, C.F.; Ford, R.C., Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J. Biol. Chem., 2003, 278 (10), 8294-8299. (Pubitemid 36800576)
78. Chang, G.; Roth, C.B., Structure of MsbA from E. coli: A homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science's STKE, 2001, 293 (5536), 1793.
79. Chang, G., RETRACTED: Structure of MsbA from Vibrio cholera: A Multidrug Resistance ABC Transporter Homolog in a Closed Conformation. J. Mol. Biol., 2003, 330 (2), 419-430. (Pubitemid 36773713)
80. Reyes, C.L.; Chang, G., Structure of the ABC transporter MsbA in complex with ADP? vanadate and lipopolysaccharide. Science, 2005, 308 (5724), 1028-1031. (Pubitemid 40664414)
81. Locher, K.P.; Lee, A.T.; Rees, D.C., The E. coli BtuCD structure: A framework for ABC transporter architecture and mechanism. Science, 2002, 296 (5570), 1091-1098. (Pubitemid 34517120)
82. Seigneuret, M.; Garnier-Suillerot, A., A structural model for the open conformation of the mdr1 P-glycoprotein based on the MsbA crystal structure. J. Biol. Chem., 2003, 278 (32), 30115.
83. Stenham, D.R.; Campbell, J.D.; Sansom, M.S.P.; Higgins, C.F.; Kerr, I.D.; Linton, K.J., An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulfide cross-linking and homology modeling. FASEB J., 2003, 17 (15), 2287-2289. (Pubitemid 39561468)
84. Pleban, K.; Kopp, S.; Csaszar, E.; Peer, M.; Hrebicek, T.; Rizzi, A.; Ecker, G.F.; Chiba, P., P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: A combined photoaffinity labeling-protein homology modeling approach. Mol. Pharmacol., 2005, 67 (2), 365-374. (Pubitemid 40216728)
85. Dawson, R.J.P.; Locher, K.P., Structure of a bacterial multidrug ABC transporter. Nature, 2006, 443 (7108), 180-185. (Pubitemid 44387602)
86. Ward, A.; Reyes, C.L.; Yu, J.; Roth, C.B.; Chang, G., Flexibility in the ABC transporter MsbA: Alternating access with a twist. Proc. Natl. Acad. Sci., 2007, 104 (48), 19005.
87. O'Mara, M.L.; Tieleman, D.P., P-glycoprotein models of the apo and ATP-bound states based on homology with Sav1866 and MalK. Febs. Lett., 2007, 581 (22), 4217-4222. (Pubitemid 47301854)
88. Globisch, C.; Pajeva, I.K.; Wiese, M., Identification of Putative Binding Sites of P-glycoprotein Based on its Homology Model. Chem. Med. Chem., 2008, 3 (2), 280-295.
89. Aller, S.G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P.M.; Trinh, Y.T.; Zhang, Q.; Urbatsch, I.L., Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science, 2009, 323 (5922), 1718-1722.
90. Harris, M.J.; Kuwano, M.; Webb, M.; Board, P.G., Identification of the apical membrane-targeting signal of the multidrug resistanceassociated protein 2 (MRP2/cMOAT). J. Biol. Chem., 2001, 276 (24), 20876-20881.
91. Campbell, J.D.; Koike, K.; Moreau, C.; Sansom, M.S.P.; Deeley, R.G.; Cole, S.P.C., Molecular modeling correctly predicts the functional importance of Phe594 in transmembrane helix 11 of the multidrug resistance protein, MRP1 (ABCC1). J. Biol. Chem., 2004, 279 (1), 463-468. (Pubitemid 38044847)
92. El-Sheikh, A.A.K.; van den Heuvel, J.J.M.W.; Krieger, E.; Russel, F.G.M.; Koenderink, J.B., Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4). Mol. Pharmacol., 2008, 74 (4), 964-971.
93. Ravna, A.W.; Sager, G., Molecular model of the outward facing state of the human multidrug resistance protein 4 (MRP4/ABCC4). Bioorg. Med. Chem. Lett., 2008, 18 (12), 3481-3483. (Pubitemid 351787578)
94. Ravna, A.W.; Sylte, I.; Sager, G., A molecular model of a putative substrate releasing conformation of multidrug resistance protein 5 (MRP5). Eur. J. Med. Chem., 2008, 43 (11), 2557-2567.
95. Li, Y.F.; Polgar, O.; Okada, M.; Esser, L.; Bates, S.E.; Xia, D., Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: A molecular modeling study. J. Mol. Graphics Model., 2007, 25 (6), 837-851. (Pubitemid 46216119)
96. Hazai, E.; Bikádi, Z., Homology modeling of breast cancer resistance protein (ABCG2). J. Struct. Biol., 2008, 162 (1), 63-74.
97. Popp, C.; Gorboulev, V.; Müller, T.D.; Gorbunov, D.; Shatskaya, N.; Koepsell, H., Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol. Pharmacol., 2005, 67 (5), 1600-1611. (Pubitemid 40594159)
98. Zhang, X.; Shirahatti, N.V.; Mahadevan, D.; Wright, S.H., A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2). J. Biol. Chem., 2005, 280 (41), 34813-34822. (Pubitemid 41504615)
99. Pelis, R.M.; Zhang, X.; Dangprapai, Y.; Wright, S.H., Cysteine accessibility in the hydrophilic cleft of human organic cation transporter 2. J. Biol. Chem., 2006, 281 (46), 35272-35280. (Pubitemid 46036565)
100. Perry, J.L.; Dembla-Rajpal, N.; Hall, L.A.; Pritchard, J.B., A Three-dimensional Model of Human Organic Anion Transporter 1. J. Biol. Chem., 2006, 281 (49), 38071-38079.
101. Zhang, X.; He, X.; Baker, J.; Tama, F.; Chang, G.; Wright, S.H., Twelve transmembrane helices form the functional core of mammalian multidrug and toxin extruder 1 (MATE1). J. Biol. Chem., 2012, 287 (33), 27971-27982.
102. Hirono, S.; Nakagome, L.; Imai, R.; Maeda, K.; Kusuhara, H.; Sugiyama, Y., Estimation of the three-dimensional pharmacophore of ligands for rat multidrug-resistance-associated protein 2 using ligand-based drug design techniques. Pharmaceut. Res., 2005, 22 (2), 260-269. (Pubitemid 40487210)
103. Zhong, L.; Ma, C.Y.; Zhang, H.; Yang, L.J.; Wan, H.L.; Xie, Q.Q.; Li, L.L.; Yang, S.Y., A prediction model of substrates and nonsubstrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput. Biol. Med., 2011, 41 (11), 1006-1013.
104. Pick, A.; Muller, H.; Mayer, R.; Haenisch, B.; Pajeva, I.K.; Weigt, M.; Bonisch, H.; Muller, C.E.; Wiese, M., Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorgan. Med. Chem., 2011, 19 (6), 2090-2102.
105. Moaddel, R.; Ravichandran, S.; Bighi, F.; Yamaguchi, R.; Wainer, I.W., Pharmacophore modelling of stereoselective binding to the human organic cation transporter (hOCT1). Brit. J. Pharmacol., 2007, 151 (8), 1305-1314. (Pubitemid 47255908)
106. Kido, Y.; Matsson, P.; Giacomini, K.M., Profiling of a Prescription Drug Library for Potential Renal Drug-Drug Interactions Mediated by the Organic Cation Transporter 2. J. Med. Chem., 2011, 54 (13), 4548-4558.
107. Litman, T.; Zeuthen, T.; Skovsgaard, T.; Stein, W.D., Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim. et Biophys. Acta (BBA)-Molecular Basis of Disease, 1997, 1361 (2), 169-176. (Pubitemid 27362090)
108. Österberg, T.; Norinder, U., Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics. Eur. J. Pharm. Sci., 2000, 10 (4), 295-303. (Pubitemid 30317465)
109. Chen, L.; Li, Y.; Yu, H.; Zhang, L.; Hou, T., Computational models for predicting substrates or inhibitors of P-glycoprotein. Drug Discov. Today, 2011, 17 (7-8), 343-351.
110. Dolghih, E.; Bryant, C.; Renslo, A.R.; Jacobson, M.P., Predicting Binding to P-Glycoprotein by Flexible Receptor Docking. Plos Computational Biology, 2011, 7 (6), e1002083.
111. Ekins, S.; Kim, R.B.; Leake, B.F.; Dantzig, A.H.; Schuetz, E.G.; Lan, L.B.; Yasuda, K.; Shepard, R.L.; Winter, M.A.; Schuetz, J.D.; Wikel, J.H.; Wrighton, S.A., Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol. Pharmacol., 2002, 61 (5), 964-973. (Pubitemid 34441760)
112. Ekins, S.; Kim, R.B.; Leake, B.F.; Dantzig, A.H.; Schuetz, E.G.; Lan, L.B.; Yasuda, K.; Shepard, R.L.; Winter, M.A.; Schuetz, J.D.; Wikel, J.H.; Wrighton, S.A., Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol., 2002, 61 (5), 974-981. (Pubitemid 34441761)
113. Pajeva, I.K.; Wiese, M., Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: Explanation of structural variety (Hypothesis). J. Med. Chem., 2002, 45 (26), 5671-5686. (Pubitemid 35453760)
114. Penzotti, J.E.; Lamb, M.L.; Evensen, E.; Grootenhuis, P.D.J., A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J. Med. Chem., 2002, 45 (9), 1737-1740. (Pubitemid 34415368)
115. Li, W.X.; Li, L.P.; Eksterowicz, J.; Ling, X.F.B.; Cardozo, M., Significance analysis and multiple pharmacophore models for differentiating P-glycoprotein substrates. J. Chem. Inf. Model., 2007, 47 (6), 2429-2438. (Pubitemid 350275107)
116. Mason, J.S.; Morize, I.; Menard, P.R.; Cheney, D.L.; Hulme, C.; Labaudiniere, R.F., New 4-point pharmacophore method for molecular similarity and diversity applications: Overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. J. Med. Chem., 1999, 42 (17), 3251-3264. (Pubitemid 29409714)
117. Bradley, E.K.; Beroza, P.; Penzotti, J.E.; Grootenhuis, P.D.J.; Spellmeyer, D.C.; Miller, J.L., A rapid computational method for lead evolution: Description and application to α1-adrenergic antagonists. J. Med. Chem., 2000, 43 (14), 2770-2774. (Pubitemid 30463926)
118. Palmeira, A.; Rodrigues, F.; Sousa, E.; Pinto, M.; Vasconcelos, M.H.; Fernandes, M.X., New Uses for Old Drugs: Pharmacophore-Based Screening for the Discovery of P-Glycoprotein Inhibitors. Chem. Biol. & Drug Des., 2011, 78 (1), 57-72.
119. Bakken, G.A.; Jurs, P.C., Classification of multidrug-resistance reversal agents using structure-based descriptors and linear discriminant analysis. J. Med. Chem., 2000, 43 (23), 4534-4541. (Pubitemid 32046878)
120. Gombar, V.K.; Polli, J.W.; Humphreys, J.E.; Wring, S.A.; Serabjit-Singh, C.S., Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J. Pharm. Sci., 2004, 93 (4), 957-968. (Pubitemid 38420406)
121. Cianchetta, G.; Singleton, R.W.; Zhang, M.; Wildgoose, M.; Giesing, D.; Fravolini, A.; Cruciani, G.; Vaz, R.J., A pharmaeophore hypothesis for P-glycoprotein substrate recognition using GRINDbased 3D-QSAR. J. Med. Chem., 2005, 48 (8), 2927-2935. (Pubitemid 40548106)
122. Li, Y.; Wang, Y.H.; Yang, L.; Zhang, S.W.; Liu, C.H.; Yang, S.L., Comparison of steroid substrates and inhibitors of P-glycoprotein by 3D-QSAR analysis. J. Mol. Struct., 2005, 733 (1-3), 111-118. (Pubitemid 39472875)
123. Cabrera, M.A.; González, I.; Fernández, C.; Navarro, C.; Bermejo, M., A topological substructural approach for the prediction of Pglycoprotein substrates. J. Pharm. Sci., 2006, 95 (3), 589-606.
124. Crivori, P.; Reinach, B.; Pezzetta, D.; Poggesi, I., Computational models for identifying potential P-glycoprotein substrates and inhibitors. Molecular Pharmaceutics, 2006, 3 (1), 33-44. (Pubitemid 43331749)
125. Huang, J.P.; Ma, G.L.; Muhammad, I.; Cheng, Y.Y., Identifying Pglycoprotein substrates using a support vector machine optimized by a particle swarm. J. Chem. Inf. Model., 2007, 47 (4), 1638-1647. (Pubitemid 47210067)
126. Bikadi, Z.; Hazai, I.; Malik, D.; Jemnitz, K.; Veres, Z.; Hari, P.; Ni, Z.L.; Loo, T.W.; Clarke, D.M.; Hazai, E.; Mao, Q.C., Predicting PGlycoprotein-Mediated Drug Transport Based On Support Vector Machine and Three-Dimensional Crystal Structure of Pglycoprotein. PloS one, 2011, 6 (10), e25815.
127. Leong, M.K.; Chen, H.B.; Shih, Y.H., Prediction of Promiscuous P-Glycoprotein Inhibition Using a Novel Machine Learning Scheme. PloS one, 2012, 7 (3), e33829.
128. Xue, Y.; Yap, C.W.; Sun, L.Z.; Cao, Z.W.; Wang, J.F.; Chen, Y.Z., Prediction of P-glycoprotein substrates by a support vector machine approach. J. Chem. Inf. Comp. Sci., 2004, 44 (4), 1497-1505.
129. de Cerqueira Lima, P.; Golbraikh, A.; Oloff, S.; Xiao, Y.; Tropsha, A., Combinatorial QSAR modeling of P-glycoprotein substrates. J. Chem. Inf. Model., 2006, 46 (3), 1245-1254. (Pubitemid 43999168)
130. Caruana, R.; Niculescu-Mizil, A. In Proceedings of the 23rd international conference on Machine learning; ACM, 2006, pp 161-168.
131. Sun, H.M., A naive Bayes classifier for prediction of multidrug resistance reversal activity on the basis of atom typing. J. Med. Chem., 2005, 48 (12), 4031-4039.
132. Wang, Y.H.; Li, Y.; Yang, S.L.; Yang, L., An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network. J. Comput. Aid. Mol. Des., 2005, 19 (3), 137-147. (Pubitemid 40974003)
133. Hammann, F.; Gutmann, H.; Jecklin, U.; Maunz, A.; Helma, C.; Drewe, J., Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein. Curr. Drug Metab., 2009, 10 (4), 339-346.
134. Chen, L.; Li, Y.Y.; Zhao, Q.; Peng, H.; Hou, T.J., ADME Evaluation in Drug Discovery. 10. Predictions of P-Glycoprotein Inhibitors Using Recursive Partitioning and Naive Bayesian Classification Techniques. Mol. Pharmaceut., 2011, 8 (3), 889-900.
135. Wang, Y.H.; Li, Y.; Yang, S.L.; Yang, L., Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J. Chem. Inf. Model., 2005, 45 (3), 750-757. (Pubitemid 40795178)
136. van de Waterbeemd, H.; Gifford, E., ADMET in silico modelling: Towards prediction paradise? Nat. Rev. Drug Discov., 2003, 2 (3), 192-204. (Pubitemid 37361664)
137. Qian, F.; Wei, D.; Zhang, Q.; Yang, S., Modulation of Pglycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells. Biomedecine & Pharmacotherapy, 2005, 59 (3), 64-69. (Pubitemid 40417515)
138. Stockner, T.; de Vries, S.J.; Bonvin, A.M.J.J.; Ecker, G.F.; Chiba, P., Data-driven homology modelling of P-glycoprotein in the ATPbound state indicates flexibility of the transmembrane domains. FEBS J., 2009, 276 (4), 964-972.
139. Tsigelny, I.F.; Kovalskyy, D.; Kouznetsova, V.L.; Balinskyi, O.; Sharikov, Y.; Bhatnagar, V.; Nigam, S.K., Conformational Changes of the Multispecific Transporter Organic Anion Transporter 1 (OAT1/SLC22A6) Suggests a Molecular Mechanism for Initial Stages of Drug and Metabolite Transport. Cell Biochem. Biophys., 2011, 61 (2), 251-259.